Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 134
- Registration Number
- NCT00737529
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Tower Cancer Research Foundation, Los Angeles, California, United States
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00735930
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2020-05-18
- Target Recruit Count
- 19
- Registration Number
- NCT00729118
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT00729638
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
- Conditions
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2019-01-22
- Target Recruit Count
- 42
- Registration Number
- NCT00727415
- Locations
- 🇮🇹
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST, Meldola, Italy
🇮🇹Unità Operativa Ematologia 1 - Università degli Studi di Bari, Bari, Italy
🇮🇹Istituto di Ematologia e Oncologia Medica "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00724568
- Locations
- 🇺🇸
Dana Farber Cancer Institute (and Massachusetts General), Boston, Massachusetts, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2013-09-27
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 10
- Registration Number
- NCT00720850
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Hamburg, Germany
🇩🇪Dresden University of Technology, Medizinische Klinik und Poliklinik 1, Dresden, Saxony, Germany
🇩🇪Universitätsklinikum Düsseldorf, Medizinische Klinik und Poliklinik, Klinik für Hämatologie, Onkologie und klinische Immunologie, Düsseldorf, Germany
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Brown University
- Target Recruit Count
- 41
- Registration Number
- NCT00717756
- Locations
- 🇺🇸
Memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States
🇺🇸Lifespan Hospitals, Providence, Rhode Island, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 1
- Registration Number
- NCT00704691
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 8
- Registration Number
- NCT00699842
- Locations
- 🇺🇸
Associates in Hematology-Oncology, PC, Chester, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.